Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-20-000974
Filing Date
2020-01-03
Accepted
2020-01-03 17:16:13
Documents
2
Period of Report
2020-01-01

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm201085d2_3.html 3  
1 OWNERSHIP DOCUMENT tm201085d2_3.xml 3 1552
2 EXHIBIT 24 tm201085d2_ex24.htm EX-24 5418
  Complete submission text file 0001104659-20-000974.txt   8609
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O TOBIRA THERAPEUTICS, INC. 701 GATEWAY BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address
Melincoff Gwen A (Reporting) CIK: 0001614890 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33357 | Film No.: 20506724